Johnson & Johnson (JNJ) to Release Earnings on Wednesday

Key Points

• Johnson & Johnson will report Q4 2025 results before the market opens on January 21, 2026 (8:30 AM ET), with analysts expecting about $2.53 EPS and $24.14 billion in revenue.
• The company beat estimates last quarter (reported $2.80 EPS on $23.99B revenue, up 6.8% YoY) and recently announced a quarterly dividend of $1.30 per share (ex-dividend Feb 24, payable Mar 10) implying a ~2.4% yield.
• Key catalysts ahead of the report include a Delaware court trimming part of a roughly $1B damages award (potentially lowering legal exposure) and positive oncology and MedTech data, though China-market pressure remains a near-term headwind.

Johnson & Johnson (NYSE:JNJ - Get Free Report) is anticipated to post its Q4 2025 results before the market opens on Wednesday, January 21st. Analysts expect the company to announce earnings of $2.53 per share and revenue of $24.1368 billion for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, January 21, 2026 at 8:30 AM ET.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Tuesday, October 14th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.76 by $0.04. The company had revenue of $23.99 billion during the quarter, compared to the consensus estimate of $23.73 billion. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.Johnson & Johnson's revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.42 EPS. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Stock Up 1.9%

Shares of NYSE:JNJ opened at $213.78 on Wednesday. The firm has a market capitalization of $515.06 billion, a PE ratio of 20.64, a price-to-earnings-growth ratio of 2.15 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $215.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm's 50-day moving average is $203.88 and its two-hundred day moving average is $185.81.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson's dividend payout ratio is presently 50.19%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Delaware’s top court threw out part of a roughly $1 billion damages award tied to J&J’s 2019 attempt to buy Auris Health and ordered a recalculation — a development that could materially reduce the company’s payout and legal overhang. Johnson & Johnson's $1 billion loss from robotics takeover reduced by Delaware top court
• Positive Sentiment: J&J reported encouraging long-term Rybrevant results in metastatic colorectal cancer — positive oncology data can raise expectations for revenue and pipeline value in oncology. Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
• Positive Sentiment: MedTech momentum is cited as a near-term growth driver, led by cardiovascular strength and new product ramps — this supports revenue upside ahead of J&J’s Q4 results. What's Powering J&J's MedTech Growth Ahead of Q4 Release?
• Positive Sentiment: New depression data (CAPLYTA, SPRAVATO and other analyses) to be presented at ACNP may improve perceptions of J&J’s CNS franchise and long-term drug commercialization prospects. Johnson & Johnson elevates leadership in depression with new data at 2026 ACNP
• Neutral Sentiment: Management’s presentation at the J.P. Morgan Healthcare Conference was published (transcript) — useful for investor modeling but largely reiterates strategy and pipeline priorities rather than new surprises. J&J Presents at 44th Annual J.P. Morgan Healthcare Conference (Transcript)
• Neutral Sentiment: Investor-letter / market commentary pieces note J&J’s strong Q4 contributions as part of broader market trends; these confirm momentum but add little incremental catalyst. Here’s What Lifted Johnson & Johnson (JNJ) in Q4
• Negative Sentiment: Despite the Delaware ruling reducing part of the award, residual legal exposure remains until damages are fully recalculated and any further appeals conclude — some uncertainty and potential liability persist. Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
• Negative Sentiment: Analysts flag lingering China market pressure for MedTech/pharma sales, which could temper near-term international growth even as other regions recover. What's Powering J&J's MedTech Growth Ahead of Q4 Release?

Hedge Funds Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Abel Hall LLC acquired a new position in Johnson & Johnson in the 3rd quarter valued at $419,000. Harvest Investment Services LLC increased its stake in shares of Johnson & Johnson by 21.4% during the third quarter. Harvest Investment Services LLC now owns 2,826 shares of the company's stock worth $524,000 after acquiring an additional 499 shares during the period. Keystone Financial Group increased its stake in shares of Johnson & Johnson by 10.1% during the third quarter. Keystone Financial Group now owns 51,405 shares of the company's stock worth $9,774,000 after acquiring an additional 4,733 shares during the period. Conservest Capital Advisors Inc. purchased a new position in Johnson & Johnson during the third quarter worth about $211,000. Finally, Morningstar Investment Management LLC lifted its position in Johnson & Johnson by 1,999.4% in the third quarter. Morningstar Investment Management LLC now owns 98,377 shares of the company's stock valued at $18,241,000 after purchasing an additional 93,691 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the subject of several recent research reports. Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 22nd. Sanford C. Bernstein lifted their target price on Johnson & Johnson from $193.00 to $208.00 and gave the company a "market perform" rating in a report on Friday. UBS Group restated a "buy" rating on shares of Johnson & Johnson in a report on Monday, January 5th. Wells Fargo & Company boosted their price objective on Johnson & Johnson from $212.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, December 12th. Finally, Weiss Ratings restated a "buy (b)" rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.